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Venoms from various predatory species, such as ﬁsh hunting molluscs scorpions, snakes and arachnids
contain a large spectrum of toxins that include blockers of voltage-gated calcium channels. These peptide
blockers act by two principal manners - physical occlusion of the pore and prevention of activation
gating. Many of the calcium channel-blocking peptides have evolved to tightly occupy their binding
pocket on the principal pore forming subunit of the channel, often rendering block poorly reversible.
Moreover, several of the best characterized blocking peptides have developed a high degree of channel
subtype selectivity. Here we give an overview of different types of calcium channel-blocking toxins, their
mechanism of action, channel subtype speciﬁcity, and potential use as therapeutic agents.
© 2016 Elsevier Ltd. All rights reserved.Contents
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Voltage-gated calcium channels are the major source of
depolarization-evoked calcium entry into excitable cells of brain,
heart, and muscle (Zamponi et al., 2015). This in turn supports
many critical physiological functions that range from muscle
contraction, to the release of neurotransmitters and calcium-
dependent gene transcription, among many others. The mamma-
lian genome encodes as many as ten different genes that lead tooni).
E., Zamponi, G.W., Block of vo
rm.2016.10.016different types of Cav subunits, the principal pore forming subunit
that forms the core of the calcium permeable ion channel (Simms
and Zamponi, 2014). They have been grouped into three major
classes (Cav1, Cav2 and Cav3) which in turn correspond to different
types of calcium currents that have been identiﬁed in native tissues
(for review, see Simms and Zamponi, 2014). The Cav1 family en-
codes four different types of L-type channels. Among the Cav2
family, Cav2.1, Cav2.2 and Cav2.3 correspond, respectively, to P/Q-
type, N-type and R-type currents. The Cav3 family represents
three different types of T-type calcium channels (also known as
low-voltage activated channels due to their hyperpolarized voltage
range of activation) (Catterall et al., 2005). Members of the Cav3
family are thought to be monomers whereas Cav1 and Cav2ltage-gated calcium channels by peptide toxins, Neuropharmacology
E. Bourinet, G.W. Zamponi / Neuropharmacology xxx (2016) 1e72channels are multimeric complexes that also include a cytoplasmic
Cavb and an extracellular Cava2d subunit (Simms and Zamponi,
2014; Catterall et al., 2005). These ancillary subunits serve pri-
marily to regulate calcium channel trafﬁcking and function, but
have also been shown to alter the pharmacological characteristics
of the channels (Dolphin, 2016). All Cav subunits share a common
transmembrane topology of four homologous transmembrane do-
mains that each contain six membrane spanning helices plus a
reentrant p-loop motif that forms the pore of the channel and
imparts calcium selectivity (Catterall et al., 2005). The fourth
transmembrane helix in each domain contains a positively charged
amino acid residue in every third position and forms the voltage
sensor of the channel (Catterall, 2010). The major domains are
connected by large cytoplasmic regions, in addition to being
ﬂanked by intracellular N- and C-terminal regions. The domain I-II
linker is the locus for Cavb subunit interactions (Pragnell et al.,
1994). The recent breakthrough resolution of the Cav1.1 channel
structure at a nearly atomic level brings us a step closer to the
understanding of the interface between the Cav subunit and
ancillary subunits (Wu et al., 2015, 2016). Notably these studies
revealed that Cava2d has a docking site formed by extracellular
segments of domains I, II, and III, all organized with other extra-
cellular loops into a dome structure above the selectivity ﬁlter.
Whether this organization is common to other Cav subtypes re-
mains to be determined.
The Cav subunit is the target for pharmacological agents that
block (and in some cases enhance) calcium channel activity
(Zamponi et al., 2015). This is relevant in the context of therapeu-
tics, as calcium channel inhibitors have been used to treat disorders
such as hypertension, pain and epilepsy (for review, see Khosravani
and Zamponi, 2006; Waxman and Zamponi, 2014; Bourinet et al.,
2014; Zamponi et al., 2015; Zamponi, 2016). Calcium channel
blockers include small inorganic ions such as cadmium which act
by occluding the permeation pathway (Lansman et al., 1986), small
organic molecules such as dihydropyridines which have been used
as a tool to identify native L-type calcium currents (Randall and
Tsien, 1995), and larger peptide-based toxins that are isolated
from a wide variety of venomous animal species. Here, we provide
an overview of different peptide toxins that act on various mem-
bers of the calcium channel superfamily, and touch on their ther-
apeutic potential.
2. u-conotoxins
The family of u-conotoxins is derived from the venoms of a
variety of different marine molluscs that use their venom to hunt
ﬁsh. They are typically between twenty and thirty amino acids in
size and display a rigid backbone structure that is spatially con-
strained by the formation of disulﬁde bonds formed between six
conserved cysteine residues (Olivera et al., 1986, 1991; Lewis et al.,
2012). Blocking afﬁnity and channel subtype selectivity vary with
amino acid sequence in the various loops between the cysteine
bonds. In general, u-conotoxins act by physically occluding the
pore of the channel, thus preventing calcium inﬂux. In many cases,
binding is very tight, leading to slow dissociation rates and hence
poorly reversible block (for example, Mintz et al., 1992; Boland
et al., 1994; Ellinor et al., 1994).
One of the deﬁning characteristics of Cav2.2 (N-type) calcium
channels is their inhibition by u-conotoxin GVIA, a 27 amino acid
peptide isolated from the ﬁsh hunting mollusc Conus geographus
(Olivera et al., 1994; McCleskey et al., 1987). GVIA block is exqui-
sitely selective for Cav2.2 channels and virtually irreversible
(Boland et al., 1994; McDonough et al., 2002), however, strong
membrane hyperpolarization has been shown to accelerate the
dissociation of this peptide from the channel (Stocker et al., 1997;Please cite this article in press as: Bourinet, E., Zamponi, G.W., Block of vo
(2016), http://dx.doi.org/10.1016/j.neuropharm.2016.10.016Feng et al., 2003). Structure-function analysis based on chimeric
calcium channel constructs has revealed that GVIA interacts with
the outer vestibule of the pore comprised of the extracellular
domain III S5eS6 (p-loop) region (Ellinor et al., 1994). Moreover,
mutations in this region (especially a Glycine residue at position
1326) have been shown to affect not only the blocking rate con-
stant, but also to have the capability to render the block reversible
(Feng et al., 2001). These data ﬁt with a structural homology model
of Cav2.2 based on the structure of bacterial sodium channels
(Lewis et al., 2012). This picture is likely to be reﬁned in light of the
recent structural data of the Cav1.1 channel in complex with a
Cava2d subunit that is docked near the top of the channel pore (Wu
et al., 2016). Such structural information may offer some mecha-
nistic insights into why the Cava2d subunit affects blocking and
unblocking rate constants for certain types of u-conotoxins (Mould
et al., 2004). The venom of Conus geographus also contains other
related u-conotoxins, such as GVIB, GVIC, GVIIA, and GVIIA, how-
ever they are not as well characterized at the electrophysiological
level as GVIA (Olivera et al., 1994).
A number of calcium channel blocking peptides have been iso-
lated from the venom of Conus magus, another ﬁsh hunting snail.
This includes u-conotoxins MVIIA, MVIIB, MVIIC, and MVIID
(Hillyard, 1992; Olivera et al., 1994), which for the most part pref-
erentially target Cav2.2 channels (Olivera et al., 1985; Monje et al.,
1993; Fox, 1995). However, MVIIC also blocks Cav2.1 calcium
channels and its blocking effects are reversible (Woppmann et al.,
1994; Grantham et al., 1994), underscoring the point that small
changes in amino acid composition between MVIIA and MVIIC are
sufﬁcient to alter channel subtype selectivity. The mode of action of
these peptides is similar to that of GIVA, and they compete for a
common interaction site on the channel (Olivera et al., 1994),
although subtle differences in the way these toxins interact with
the channel have been suggested (Woppmann et al., 1994).
MVIIA has received particular attention, as this peptide can be
synthesized such that it retains its native conformation (Xiao and
Bennett, 1995). This has allowed the exploration of this peptide as
a therapeutic agent for pain, based on the underlying principle that
the Cav2.2 channel plays a major role in the transmission of pain
signals in the spinal dorsal horn (Bourinet et al., 2014). Intrathecal
delivery of MVIIA (a.k.a. ziconotide or Prialt) mediates analgesic
effects in both animals and humans. However, although Prialt is
approved for treating intractable cancer pain in humans it has a
narrow therapeutic window and the potential for causing severe
CNS side effects (Antanassoff et al., 2000; Penn and Paice, 2000;
Miljanich, 2004; Staats et al., 2004; Thompson et al., 2006;
Wallace et al., 2006; Ver et al., 2008). The toxicity of MVIIA has
recently been attributed to a methionine residue at position 12 of
the toxin molecule, which is known to dock to a hydrophobic
binding pocket comprised of residues I300, F302, L305 of the
Cav2.2 subunit (Wang et al., 2016).
A number of additionalu-conotoxins have been identiﬁed in the
venoms of Conus fulman and Conus catus and shown to mediate
potent inhibition of Cav2.2 channels and to exhibit analgesic ef-
fects. This includes u-conotoxins FVIA (a reversible N-type channel
blocker; Lee et al., 2010), as well as CVIB (Motin et al., 2007), CVID
(Lewis et al., 2000; Scott et al., 2002; Adams et al., 2003), CVIE and
CVIF (Berecki et al., 2010). Interestingly, CVID and CVIE (but not
CVIF) mediate analgesia in mice even after systemic administration
(Sadeghi et al., 2013). Of further note, CVID has been advanced to
human clinical trials where a larger therapeutic window was
observed compared with Prialt (Schroeder et al., 2006), however,
this peptide did to our knowledge not advance beyond phase II.
Nonetheless, the larger therapeutic window has been attributed to
the fact that CVID shows greater selectivity for Cav2.2 channels
over Cav2.1.ltage-gated calcium channels by peptide toxins, Neuropharmacology
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Conus striatus venom. Although they are pore blockers, it has been
suggested that their sites of action are distinct from those of GVIA
(Ramilo et al., 1992). Moreover, similar to MVIIC, SVIB reversibly
blocks Cav2.2 and Cav2.1 channels (Woppmann et al., 1994; Nielsen
et al., 1996).
The venoms of Conus Victoriae and Conus regis, respectively,
contain a-conotoxins Vc1.1 and Rg1A. These peptides were classi-
ﬁed as a-conotoxins in line with their action on nicotinic acetyl-
choline receptors (Clark et al., 2006; Nevin et al., 2007).
Subsequently, potent inhibition by these toxins of Cav2.2 calcium
channels was reported. However, both Vc1.1 and Rg1A do not act
directly on the channel, but instead by activating GABAB receptors
(Callaghan et al., 2008; Callaghan and Adams, 2010; Cuny et al.,
2012; Huynh et al., 2015). This is thought to occur by interference
with the receptor dimer ectodomain interface (Adams and Berecki,
2013), which then triggers inhibition of Cav2.2 channels via a G
protein pathway. By doing so, the Vc1.1 peptide produces analgesia
in rodent models of neuropathic and gastrointestinal pain, and
reduces the excitability of human dorsal root ganglion neurons
(Klimis et al., 2011; Castro et al., 2016). Vc1.1 is being explored as a
possible pain therapeutic for humans, and this has been facilitated
through the generation of a cyclized version of the peptide that
remarkably allows oral delivery of Vc1.1 (Carstens et al., 2011).
While the majority of u-conotoxins appear to target Cav2.2 and
Cav2.1 calcium channels, there are some examples of L-type cal-
cium channel blocking u-conotoxins. For example, u-conotoxin
TxVII from Conus textile blocks L-type calcium channels from a
freshwater pond snail, Lymnaea stagnalis (Fainzilber et al., 1996).
Glacontryphan-M, an unusual peptide isolated from the venom of
Conus marmoreus contains g-carboxyglutamyl (Gla) residues in
positions 2 and 4 that bestow calcium binding ability onto this
toxin. It has been shown to block L-type currents in mouse
pancreatic beta cells (Hansson et al., 2004). Block, however, was
found to be incomplete with ~35% inhibition at saturating con-
centrations. Substitution of the Gla residues with glutamate abol-
ished block, as did removal of extracellular calcium.
3. u-Agatoxins
The venom of the American funnel-web spider Agenelopsis
aperta contains a number of different neurotoxins, including the
calcium channel blocking u- agatoxins (Adams et al., 1993. Olivera
et al., 1994). Among these, u-agatoxin IVA has been used as an
experimental tool to identify and distinguish native P- and Q-type
currents (Adams et al., 1993; Llinas et al., 1986; Turner et al., 1992),
with P-type currents showing an approximately ten-fold greater
sensitivity to this toxin. Both P-type and Q-type currents are sup-
ported by different variants of Cav2.1 channels (i.e., different splice
isoforms), and differential assembly with different types of ancil-
lary Cavb subunits (Bourinet et al., 1999; Mermelstein et al., 1999),
with alternate splicing of an asparagine-proline motif in the
domain IV S3eS4 linker greatly affecting blocking afﬁnity (Bourinet
et al., 1999). This region is implicated further in toxin block by a
study that examined the role of a speciﬁc glutamate residue that
appears to be critical for toxin block (Winterﬁeld and Swartz,
2000). u-agatoxin IVA is somewhat larger than the family of u-
conotoxins (i.e., 48 amino acids), but also has constrained backbone
structure through formation of as many as four disulﬁde bonds
(Olivera et al., 1994).
Unlike the u-conotoxins, u-agatoxin IVA does not cause pore
block, but instead acts as a gating inhibitor (Fig. 1). Binding of the
toxin antagonizes the activation of the channel by preventing the
movement of the voltage sensor domains (Mintz et al., 1992;
McDonough et al., 1997a; Bourinet et al., 1999), which ﬁts thePlease cite this article in press as: Bourinet, E., Zamponi, G.W., Block of vo
(2016), http://dx.doi.org/10.1016/j.neuropharm.2016.10.016notion that toxin binding occurs at a region adjacent to the voltage
sensor in domain IV. This inhibition can be overcome by application
of strong depolarizing voltage pulses (Mintz et al., 1992). The
voltage-induced reversibility of blocking action is also reﬂected in a
massive (i.e., many tens of millivolts) shift in the apparent half-
activation potential of the channel that is and likely due to dis-
lodging of the toxin from its binding site by virtue of outward
voltage sensor movement (Mintz et al., 1992). Although u-agatoxin
IVA is selective for Cav2.1channels, higher concentrations of this
toxin also have the propensity to affect other members of the Cav2
channel family, including Cav2.2 (Sidach and Mintz, 2000) and
Cav2.3 (Williams et al., 1994).
A much larger member of the u-agatoxin family is u-agatoxin
IIIA (Venema et al., 1992; Olivera et al., 1994). It is nearly double in
size compared to IVA (78 amino acid residues) and contains as
many as 12 cysteine residues that are capable of six disulﬁde bonds
(Olivera et al., 1994). This toxin has poor selectivity among the
family of high-voltage activated channels, blocking L-type, P/Q-
type and N-type channels, whereas T-type calcium channels
appear to be spared (Mintz et al., 1991; Mintz, 1994). This toxin acts
as a pore blocker, however, a residual current remains even at
saturating concentrations. In Cav2.2 channels, this residual current
is insensitive to u-conotoxin GVIA, indicating that u-agatoxin IIIA
may act via incomplete pore occlusion (Mintz, 1994). In contrast, in
P-type channels, u-agatoxin IVA blocks this residual current,
consistent with the idea that u-agatoxin IVA does not require ac-
cess to the pore of the channel (Mintz, 1994).
The American funnel web spider also produces two other u-
agatoxins, namely u-agatoxin IA and IIA. The former appears to be
speciﬁc for insect calcium channels, whereas the latter blocks both
mammalian and invertebrate channels (Olivera et al., 1994). The
two toxins differ in structure, with u-agatoxin IA being a hetero-
dimer with ﬁve disulﬁde bonds (Santos et al., 1992), andu-agatoxin
IIA displaying only three disulﬁde bonds.
4. Other toxins from spiders and scorpions
The venom of the tarantula Grammostola spatulata contains a
calcium channel blocking peptide termed u-grammotoxin SIA. This
toxin acts on Cav2.1, Cav2.2 and Cav2.3 channels with micromolar
afﬁnity (Lampe et al., 1993; Piser et al., 1994, 1995; McDonough
et al., 1997b; Turner et al., 1995). u-grammotoxin SIA is a gating
modiﬁer whose action is reminiscent of that of u-agatoxin IVA
(McDonough et al., 1997a), such that it produces a massive shift in
the half-activation potential of the channel. Interestingly, the ef-
fects of u-grammotoxin SIA and u-agatoxin IVA on Cav2.2 channels
are additive, such that the apparent half activation voltage of the
channels is shifted by as much as þ150 mV when both toxins are
present (McDonough et al., 1997b). This ﬁnding implies that the
two toxins, although both acting by preventing voltage-sensor
movement, target distinct sites or domains of the Cav2.2 subunit.
Binding studies reveal that u-conotoxin GVIA cannot displace u-
grammotoxin SIA from its binding site (Lampe et al., 1993),
consistent with the notion that the latter is not a pore blocker.
Huwenotoxin-1 is a 33 amino acid peptide isolated from the
spider Selenocosmia huwena. It has been shown to bock N-type
currents in NG108-15 cells with an afﬁnity of approximately 100 nM
(Peng et al., 2001). L-type calcium channels were also shown to be
targeted by this peptide, but with much lower afﬁnity. Low-voltage
activated channels were not affected (Peng et al., 2001). Based on its
folding pattern, Huwenotoxin-1 likely acts though a pore blocking
mechanism similar to that of u-conotoxin MVIIA.
Venom from the tarantulaHysterocrates gigas contains a calcium
channel blocking peptide termed SNX-482 which is a potent in-
hibitor of Cav2.3 calcium channels (Newcomb et al., 1998). Like u-ltage-gated calcium channels by peptide toxins, Neuropharmacology
Fig. 1. Comparison of action of pore blockers and gating modiﬁers. A. Pore blockers such as u-conotoxin MVIIA act by binding to amino acid residues in the outer vestibule of the
channel pore, thus physically occluding the permeation pathway. Hence, at sub-saturating concentrations, there is a reduction of whole cell conductance across the entire spectrum
of voltages without an apparent shift in the voltage-dependence of activation (bottom panel). B, Gating modiﬁers such as u-agatoxin IVA bind to a site located outside of the
permeation pathway that is coupled to the activation gating machinery. Toxin binding thus prevents channel opening, and hence calcium entry through the channel. Strong
membrane depolarizations can overcome this effect, allowing full channel opening at very depolarized membrane potentials. This is reﬂected in a rightward shift of the activation
curve of the channel (bottom panel).
E. Bourinet, G.W. Zamponi / Neuropharmacology xxx (2016) 1e74grammotoxin SIA and u-agatoxin IVA, this toxin triggers a shift in
half activation potential of Cav2.3 channels by approximately
70 mV, indicating that it too is an activation gating modiﬁer. This
peptide also blocks Cav1.2 calcium channels, albeit incompletely
(Bourinet et al., 2001). Although its precise site of action on Cav2.3
channels is unknown, block appears to involve domains III and IV of
the channel as revealed by chimeras between Cav2.3 and Cav1.2.
These ﬁndings indicate that despite their high afﬁnity for calcium
channels, peptides trapping voltage-sensing domains have pro-
miscuous effects on distinct channels. This has been well docu-
mented for voltage-gated sodium channels (Bosmans and Swartz,
2010). Along these lines, SNX482 was recently shown to potently
affect Kv4.2 and 4.3 potassium channels, suggesting that caution is
warranted in the interpretation of neurophysiological data ob-
tained with this peptide (Kimm and Ben, 2014). Nonetheless, SNX-
482 was demonstrated to have interesting effects on the descend-
ing pathways controlling opiate analgesia and on reducing
morphine tolerance to pain, an effect that is mirrored in the Cav2.3
KO mice (Yokoyama et al., 2004).
SNX-325 is a 31 amino acid long peptide found in the venom of
the spider Segestria ﬂorentina that contains 6 cysteine residues
(Newcomb et al., 1995). It preferentially blocks Cav2.2 calcium
channels, but can target other members of the high-voltage acti-
vated calcium channel family at higher concentrations. Since it is
able to displace u-conotoxinMVIIA from its binding site (Newcomb
et al., 1995) this toxin likely acts as a pore blocker.
The venom of the scorpion Parabuthus transvaalicus contains
kurtoxin, a 63 amino acid peptide that was the ﬁrst published
example of a toxin acting on a member of the T-type calcium
channel family (Chuang et al., 1998). However, subsequent studies
have revealed that this peptide also targets members of the Cav1
and Cav2 channel families (Sidach and Mintz, 2002), in addition to
voltage-gated sodium channels (Zhu et al., 2009). At least for Cav3
channels, kurtoxin acts as a gating modiﬁer (Sidach and Mintz,
2002). The solution structure of kurtoxin reveals striking similar-
ities to a-scorpion toxins, but somewhat different surface proper-
ties that may explain why this toxin acts on Cav3 channels in
addition to sodium channels (Lee et al., 2012).Please cite this article in press as: Bourinet, E., Zamponi, G.W., Block of vo
(2016), http://dx.doi.org/10.1016/j.neuropharm.2016.10.016Finally, protoxins I and II, found in the venom of the Tarantula
Thrixoppelma pruriens, are potent sodium channel blockers
(Middleton et al., 2002; Schmalhofer et al., 2008; Xiao et al., 2010),
however, they have also been shown to potently block Cav3 calcium
channels (Edgerton et al., 2010; Bladen et al., 2014). Protoxin I
preferentially blocks Cav3.1 over Cav3.3 channels with about one
order of magnitude higher afﬁnity (Ohkubo et al., 2010; Bladen
et al., 2014). This toxin appears to interact with residues in the
domain IV region with some contribution from sites located in
domain II of the Cav3.1 channels. In contrast, Cav3.2 channels are
blocked with about 100-fold lower afﬁnity. There appears to be
some conservation in the binding sites of this toxin on Cav3 and
Nav channels (Bladen et al., 2014). In contrast, protoxin II acts
preferentially on Cav3.2 calcium channels and causes a curious shift
in the half-inactivation potential of the channel (Bladen et al., 2014)
that remains to be further explored. Recent structure function ex-
periments inwhich the voltage sensing domains of Cav3.1 channels
were transferred individually onto a Kv2.1 backbone have revealed
that protoxin II may preferentially target the voltage sensor in
domain III of Cav3 channels (Salari et al., 2016).
Additional toxins have been isolated from the Parabuthus
transvaalicus scorpion (i.e., KLI and KLII) and the tarantula Ther-
aphosidae (PsPTx3). The former two peptides block T-type channels
and sodium channels (Olamendi-Portugal et al., 2002), whereas the
latter preferentially targets T-type calcium channels, with some
selectivity for Cav3.2 (E. Bourinet, unpublished observations, patent
WO 2010081971 A1).
In summary, a number of calcium channel blocking peptides
from various arachnids have been shown to block voltage-gated
calcium channels. Many of these act as gating modiﬁers, however,
the evolutionary signiﬁcance of gating block as opposed to pore
occlusion in peptide toxins from spiders versus cone snails remains
to be determined.
5. Calcium channel blocking toxins from snakes
Black mamba (Dendroaspis polylepis) venom contains calci-
septine, a 60 amino acid peptide (de Weille et al., 1991). Thisltage-gated calcium channels by peptide toxins, Neuropharmacology
E. Bourinet, G.W. Zamponi / Neuropharmacology xxx (2016) 1e7 5peptide has been shown to selectively block L-type calcium chan-
nels from brain and heart (de Weille et al., 1991), and was subse-
quently shown to compete with dihydropyridine binding to
synaptosomes (Yasuda et al., 1993). Interestingly, this peptide ap-
pears to have an agonist function on Cav1.1 channels in skeletal
muscle (García et al., 2001). FS2 is a related 60 amino acid peptide,
also from black mamba venom, that differs from calciseptine in
three amino acids. Like calciseptine, it potently blocks L-type cal-
cium channels in smooth muscle (Yasuda et al., 1994).
Calcicludine is a 60 amino acid peptide isolated from the venom
of the green mamba Dendroaspis angusticeps. It has been shown to
block high-voltage activated calcium channels in cerebellar granule
cells with high afﬁnity (Schweitz et al., 1994), with L-type channels
being most effectively inhibited. The effects of this toxin were also
studied on heterologously expressed channels (Stotz et al., 2000),
revealing several interesting features. First, block of Cav1.2, Cav2.1,
Cav2.2 and Cav2.3 channels was found to be irreversible and
incomplete at saturating concentrations, with Cav1.2 channels
exhibiting the greatest degree of inhibition. Second, for Cav2
channels, the toxin induced a small hyperpolarizing shift in half-
activation potential, leading to a current enhancement at negative
membrane potentials. Finally, experiments with chimeric calcium
channels revealed that multiple membrane domains are involved
in toxin block. Calcicludine binding was subsequently shown to
mediate allosteric coupling to the dihydropyridine binding site
(Wang et al., 2007) in line with experiments involving calciseptine
(Yasuda et al., 1993).
Altogether, mamba venom contains at least three related pep-
tide toxins that remarkable all are 60 amino acids in length, and all
act by inhibiting L-type channel activity.
6. How useful are calcium channel peptide toxins as
therapeutics?
Peptide toxins isolated from predatory species such as cone
snails have long been explored as possible therapeutics, and is
exempliﬁed by the fact that entire research conferences have been
dedicated to this subject (for example, Venoms to Drugs). With
regard to calcium channel blocking peptides, most effort has been
focused on their utility as potential analgesics. This is due to the fact
that these peptides, which do not normally cross the blood brain
barrier and can thus typically not be administered systemically, can
be delivered to key sites of action in the pain pathway intrathecally.
The only clinically approved calcium channel blocking peptide so
far is Prialt (u-conotoxin MVIIA) (Staats et al., 2004). However, it
can hardly be described as a blockbuster drug, and both the need
for intrathecal delivery via an implantedmini pump and the limited
therapeutic index is severely limiting (Ver et al., 2008). Modiﬁca-
tion of the peptide structure into cyclized versions may provide a
means for oral delivery, and thus the potential for much wider
application for clinical use in humans. However, although there is
now proof of concept with Vc1.1, producing such orally available
peptides without loss of speciﬁcity and afﬁnity remains chal-
lenging. Nonetheless, in addition to having been established as
important and selective tools for isolation of native calcium cur-
rents (Randall and Tsien, 1995), peptide toxins retain promise as
possible therapeutic agents, as either drugs, or templates for small
organic mimetics. The resolution of the Cav1.1 structure may help
advance the discovery of such peptide mimetics.
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